Fluad Adjuvant Could Come Under Fire At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.
You may also be interested in...
CSL's Fluad Seems Headed For Post-Marketing Safety Study
Adjuvanted seasonal influenza vaccine should get accelerated approval but needs confirmatory trial to address imbalance in deaths following revaccination, FDA advisory committee says.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.
Novartis Flu Vaccine Nightmare Ends; Worries Over Pharmacovigilance Overreaction Remain
As Italy, France, Switzerland and Austria lift bans on two Novartis flu vaccines, Germany’s more sober approach to specific batch suspensions proves more palatable for manufacturers.